Virtu Financial’s Pacira BioSciences PCRX Stock Holding History

Virtu Financial’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-9,089	Closed	-$351K	–	1955
2022 Q4	$351K	Buy	+9,089	New	+$442K	0.05%	416

Other funds holding PCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

Virtu Financial's PCRX Position: Q1 2023 in Review

Virtu Financial sold out of Pacira BioSciences (PCRX) in Q1 2023, closing a stake of 9,089 shares — an estimated $351K sold.

Virtu Financial first reported a position in PCRX in Q4 2022 and held it in 1 quarter. The position peaked at $351K in Q4 2022. 267 funds tracked by Wall St. Rank hold PCRX as of Q1 2023.

Virtu Financial reported no remaining Pacira BioSciences position as of Q1 2023 after selling out during the quarter.
Virtu Financial sold 9,089 Pacira BioSciences shares in Q1 2023, an estimated $351K.
Virtu Financial first reported a position in Pacira BioSciences in Q4 2022 and held it in 1 quarter.
Virtu Financial's Pacira BioSciences position peaked at $351K in Q4 2022.
267 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2023.

Based on Virtu Financial's 13F filing for Q1 2023, filed 1 May 2023.